184 related articles for article (PubMed ID: 25328952)
21. Prostate specific antigen testing: age-related interpretation in early prostate cancer detection.
McKenzie PR; Delahunt B; Kench JG; Ross B; Lam Q; deVoss K; Tran HA; Sikaris KA
Pathology; 2013 Jun; 45(4):343-5. PubMed ID: 23619589
[No Abstract] [Full Text] [Related]
22. PSA in men in their 40s predicts risk of prostate cancer death.
Rees J
Practitioner; 2013 Sep; 257(1764):5. PubMed ID: 24383151
[No Abstract] [Full Text] [Related]
23. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
Carter HB
BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
[TBL] [Abstract][Full Text] [Related]
24. [Significance of the PSA-concentration for the detection of prostate cancer].
Stachon A
Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
[TBL] [Abstract][Full Text] [Related]
25. Re: The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Taneja SS
J Urol; 2015 Jan; 193(1):127. PubMed ID: 25523657
[No Abstract] [Full Text] [Related]
26. Two-Stage Biomarker Protocols for Improving the Precision of Early Detection of Prostate Cancer.
Barnett CL; Tomlins SA; Underwood DJ; Wei JT; Morgan TM; Montie JE; Denton BT
Med Decis Making; 2017 Oct; 37(7):815-826. PubMed ID: 28363265
[TBL] [Abstract][Full Text] [Related]
27. [You have to take the prostate cancer seriously].
Stief CG
MMW Fortschr Med; 2012 Jan; 154(1):42. PubMed ID: 22642002
[No Abstract] [Full Text] [Related]
28. [Does a low PSA at 60 years old exclude the risk of developing prostate carcinoma?].
Zürcher S
Rev Med Suisse; 2014 Jun; 10(434):1316. PubMed ID: 25073308
[No Abstract] [Full Text] [Related]
29. An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis.
Ishikawa T; Yoneyama T; Tobisawa Y; Hatakeyama S; Kurosawa T; Nakamura K; Narita S; Mitsuzuka K; Duivenvoorden W; Pinthus JH; Hashimoto Y; Koie T; Habuchi T; Arai Y; Ohyama C
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241428
[TBL] [Abstract][Full Text] [Related]
30. [PROBASE study - optimizing PSA screening].
Setton J
Aktuelle Urol; 2013 Nov; 44(6):431. PubMed ID: 24281932
[No Abstract] [Full Text] [Related]
31. [PSA and hK2 in the diagnosis of prostate cancer].
Alapont Alacreu JM; Navarro Rosales S; Budía Alba A; España Furió F; Morera Martínez F; Jiménez Cruz JF
Actas Urol Esp; 2008 Jun; 32(6):575-88. PubMed ID: 18655340
[TBL] [Abstract][Full Text] [Related]
32. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
33. [BIOMARKERS OF EARLY AND DIFFERENTIAL DIAGNOSIS OF PROSTATIC CANCER].
Grygorenko VM; Danylets RO; Vikarchuk MV; Gorbahn LV; Klepko AV
Klin Khir; 2017; (1):54-7. PubMed ID: 30272918
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
Black A; Berg CD
Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
[TBL] [Abstract][Full Text] [Related]
35. Re: Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves.
Jacobsen SJ; Guess HA; Oesterling JE
J Urol; 1996 Apr; 155(4):1395-6. PubMed ID: 8632594
[No Abstract] [Full Text] [Related]
36. Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia.
Kitagawa Y; Namiki M
Asian J Androl; 2015; 17(3):475-80. PubMed ID: 25578935
[TBL] [Abstract][Full Text] [Related]
37. Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey.
Leyva B; Persoskie A; Ottenbacher A; Hamilton JG; Allen JD; Kobrin SC; Taplin SH
J Cancer Educ; 2016 Dec; 31(4):693-701. PubMed ID: 26498649
[TBL] [Abstract][Full Text] [Related]
38. [Social gradient of PSA screening? 8 years follow up from the cancer registry of the tumor center in Regensburg].
Klotz T; Mathers MJ; Gerken M; Klinkhammer-Schalke M; Hofstädter F
Urologe A; 2010 Dec; 49(12):1503-7. PubMed ID: 20945060
[TBL] [Abstract][Full Text] [Related]
39. [PSA 2010--the beginning of a new era in early detection of prostate cancer].
Börgermann C; Sieverding M; Fornara P; Graefen M; Hammerer P; Semjonow A; Schröder F; Rübben H
Urologe A; 2006 Sep; 45 Suppl 4():127-33. PubMed ID: 16941115
[No Abstract] [Full Text] [Related]
40. Screening for prostate cancer: prostate-specific antigen testing is not effective.
Hitzeman N; Molina M
Am Fam Physician; 2011 Apr; 83(7):802-4. PubMed ID: 21524045
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
